Endomag's Magtrace receives wider FDA approval for lumpectomy patients
7 December 2022
UCLB spinout Endomag uses magnetics to remove the need for radioactivity when staging breast cancer, commonly through a procedure called sentinel lymph node biopsy.
In 2018, Endomag’s technology, Magtrace, was initially approved for patients undergoing a mastectomy procedure. Since that original submission, additional data has been submitted to the FDA which has now validated its use for all breast cancer patients, leading to an expansion to all patients choosing breast conserving surgery too.
This news is a major milestone for both breast cancer patients and physicians across the US, helping to improve access and reduce the reliance on nuclear medicine alternatives.
Read the full story from Endomag.
Read the UCLB case study here.